Halper Sadeh LLC Encourages GIFI, MOVE, RMBI, CDTX Shareholders to Contact the Firm to Discuss Their Rights
Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-NUVSF, NDTAF, THS, and CDTX
Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025 [Forbes]
Cidara Therapeutics (NASDAQ:CDTX) had its "neutral" rating reaffirmed by analysts at Guggenheim.